Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

ChemBridge Corp. and University of Hong Kong In Possible…

By Pharmaceutical Processing | October 12, 2004

SAN DIEGO, CA (October 12, 2004) – ChemBridge Corp. and the University of Hong Kong recently announced a potentially significant breakthrough in the early stages of research in the fight against Severe Acute Respiratory Syndrome (SARS), the coronavirus infection that affected more than 8,000 people, killing some 800, mainly in Hong Kong and China, during the period April-June 2003.

Richard Kao, research assistant professor from the University of Hong Kong’s Department of Microbiology, and his team used chemical genetics methods to screen aChemBridge library of more than 50,000 compounds in an attempt to identify smallmolecules that stop the spread of the coronavirus, ChemBridge said.

Dr. Kao’s team reportedly found a number of compounds that effectively inhibited the spread of the disease. The group is now working on identifying the mechanisms by which these compounds work in an effort to bring a SARS cure to the marketplace.

“The pioneering works of Schreiber (Harvard University) and Stockwell (MIT) have laid down the foundation of chemical genetics,” Kao said. “We just followed their foot steps and extended this new research paradigm to emerging infectious diseases — an increasingly alarming problem regionally and globally.”

The work has been published – Richard Y. Kao, Wayne H.W. Tsui, Terri S.W. Lee, Julian A. Tanner, Rory M. Watt, Jian-Dong Huang, Lihong Hu, Guanhua Chen, Zhiwei Chen, Linqi Zhang, Tian He, Kwok-Hung Chan, Herman Tse, Amanda P.C. To, Louisa W.Y. Ng, Bonnie C.W. Wong, Hoi-Wah Tsoi, Dan Yang, David D. Ho, and Kwok-Yung Yuen: “Identification of Novel Small-Molecule Inhibitors of Severe Acute Respiratory Syndrome-Associated Coronavirus by Chemical Genetics.” Chemistry & Biology, Volume 11, Number 9, September 2004, pp. 1293-1299.

ChemBridge Corp. is a provider of chemistry tools and contract research services for small molecule drug discovery. Founded in 1993, it is a privately held company with about 350 employees.

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE